Sign In
Buy RFL
$1.35
-0.0200 (-1.46%)
At Close: Jun 03, 2026
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
05:04pm, Wednesday, 13'th Mar 2024
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
04:01pm, Thursday, 14'th Dec 2023
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments Company remains focused on generating shareholder
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
04:01pm, Monday, 30'th Oct 2023
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities Company positions itself to generate value for its stockho
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
08:16am, Wednesday, 02'nd Aug 2023
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changin
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
11:43am, Tuesday, 23'rd Aug 2022 GlobeNewswire Inc.
NEWARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today announced that it has closed on the
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
09:35am, Tuesday, 12'th Jul 2022 Benzinga
Gainers
Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) sha
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session
04:11pm, Monday, 11'th Jul 2022 Benzinga
Gainers
Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.
La Jolla Pharm
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
12:25pm, Friday, 08'th Jul 2022 Benzinga
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
06:14pm, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Raf
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
08:01pm, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for th
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
12:00pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael P
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
03:04pm, Tuesday, 24'th May 2022 GlobeNewswire Inc.
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results
08:01pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for t
The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors
09:00pm, Friday, 11'th Mar 2022 Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2022, Rafael disclosed that its previously issued financial statements for the quarter ended October 31, 2021 “should no longer be relied upon because the Com
